Assignee
INDIVIOR UK LTD
GB·32 granted patents·17 pending applications·150 citations·filing 2014–2025
Top patents by PatentIndex Score
49 records- 0196US9827241B2Injectable flowable composition comprising buprenorphineINDIVIOR UK LTD·Filed 2017·Granted Nov 28, 2017·13 cites·58 claims
- 0296US9782402B2Injectable composition comprising buprenorphineINDIVIOR UK LTD·Filed 2016·Granted Oct 10, 2017·16 cites·60 claims
- 0396US9498432B2Injectable flowable composition comprising buprenorphineINDIVIOR UK LTD·Filed 2016·Granted Nov 22, 2016·19 cites·16 claims
- 0494US10376590B2Sustained delivery formulations of risperidone compoundINDIVIOR UK LTD·Filed 2017·Granted Aug 13, 2019·10 cites·45 claims
- 0594US10198218B2Injectable flowable composition comprising buprenorphineINDIVIOR UK LTD·Filed 2017·Granted Feb 5, 2019·7 cites·35 claims
- 0694US10058554B2Sustained release small molecule drug formulationINDIVIOR UK LTD·Filed 2017·Granted Aug 28, 2018·12 cites·20 claims
- 0794US9180197B2Sustained delivery formulations of risperidone compoundsINDIVIOR UK LTD·Filed 2014·Granted Nov 10, 2015·14 cites·7 claims
- 0893US10592168B1Injectable flowable composition comprising buprenorphineINDIVIOR UK LTD·Filed 2019·Granted Mar 17, 2020·5 cites·22 claims
- 0993US9186413B2Sustained delivery formulations of risperidone compoundsINDIVIOR UK LTD·Filed 2014·Granted Nov 17, 2015·13 cites·12 claims
- 1092US10406160B2Sustained release small molecule drug formulationINDIVIOR UK LTD·Filed 2018·Granted Sep 10, 2019·8 cites·20 claims
- 1191US10558394B2Injectable flowable composition comprising buprenorphineINDIVIOR UK LTD·Filed 2017·Granted Feb 11, 2020·5 cites·28 claims
- 1290US11110093B2Sustained release small molecule drug formulationINDIVIOR UK LTD·Filed 2019·Granted Sep 7, 2021·2 cites·20 claims
- 1390US10022367B2Sustained-release buprenorphine solutionsINDIVIOR UK LTD·Filed 2015·Granted Jul 17, 2018·9 cites·49 claims
- 1489US11013809B2Sustained delivery formulations of risperidone compoundINDIVIOR UK LTD·Filed 2019·Granted May 25, 2021·4 cites·30 claims
- 1588US2026085060A1Therapeutic compoundsINDIVIOR UK LTD·Filed 2025·Application pending·0 cites
- 1685US11839611B2Buprenorphine dosing regimensINDIVIOR UK LTD·Filed 2021·Granted Dec 12, 2023·2 cites·23 claims
- 1783US12441709B2Therapeutic compoundsINDIVIOR UK LTD·Filed 2023·Granted Oct 14, 2025·0 cites·13 claims
- 1883US2023135427A1Sustained delivery formulations of risperidone compoundINDIVIOR UK LTD·Filed 2022·Application pending·0 cites
- 1981US10172849B2Compositions comprising buprenorphineINDIVIOR UK LTD·Filed 2016·Granted Jan 8, 2019·3 cites·18 claims
- 2078US11712475B2Sustained delivery formulations of risperidone compoundINDIVIOR UK LTD·Filed 2021·Granted Aug 1, 2023·0 cites·12 claims
- 2177US11135216B2Sublingual and buccal film compositionsINDIVIOR UK LTD·Filed 2019·Granted Oct 5, 2021·0 cites·9 claims
- 2276US10000477B2Dopamine D3 receptor antagonist compoundsINDIVIOR UK LTD·Filed 2015·Granted Jun 19, 2018·2 cites·33 claims
- 2375US9687454B2Sublingual and buccal film compositionsINDIVIOR UK LTD·Filed 2016·Granted Jun 27, 2017·1 cites·14 claims
- 2472US10239870B2Dopamine D3 receptor antagonistsINDIVIOR UK LTD·Filed 2018·Granted Mar 26, 2019·1 cites·40 claims
- 2572US2023077787A1Buprenorphine dosing regimensINDIVIOR UK LTD·Filed 2022·Application pending·0 cites
- 2671US10273244B2Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulatorsINDIVIOR UK LTD·Filed 2016·Granted Apr 30, 2019·1 cites·22 claims
- 2770US11000520B2Buprenorphine dosing regimensINDIVIOR UK LTD·Filed 2015·Granted May 11, 2021·1 cites·23 claims
- 2869US2025213553A1Buprenorphine dosing regimensINDIVIOR UK LTD·Filed 2025·Application pending·0 cites
- 2968US10646484B2Methods to treat opioid use disorderINDIVIOR UK LTD·Filed 2018·Granted May 12, 2020·1 cites·29 claims
- 3068US2025127765A1Rapid induction with monthly injectable buprenorphine extended-releaseINDIVIOR UK LTD·Filed 2024·Application pending·0 cites
- 3165US11478407B2Syringe systemINDIVIOR UK LTD·Filed 2018·Granted Oct 25, 2022·1 cites·9 claims
- 3263US11857498B2Syringe systemINDIVIOR UK LTD·Filed 2022·Granted Jan 2, 2024·0 cites·23 claims
- 3363US10654842B2Dopamine D3 receptor antagonist compoundsINDIVIOR UK LTD·Filed 2019·Granted May 19, 2020·0 cites·20 claims
- 3463US2017209431A1Sublingual and buccal film compositionsINDIVIOR UK LTD·Filed 2017·Application pending·0 cites
- 3563US2024408003A1Compositions, devices and methods for the treatment of alcohol use disorderINDIVIOR UK LTD·Filed 2023·Application pending·0 cites
- 3662US2018360822A1Intranasal naloxone compositions and methods of making and using sameINDIVIOR UK LTD·Filed 2018·Application pending·0 cites
- 3760US10149912B2Dehydrated hydrogel inclusion complexINDIVIOR UK LTD·Filed 2016·Granted Dec 11, 2018·0 cites·20 claims
- 3858US10517864B2Sustained-release buprenorphine solutionsINDIVIOR UK LTD·Filed 2018·Granted Dec 31, 2019·0 cites·22 claims
- 3958US2025352522A1Rapid induction with monthly injectable buprenorphine extended-releaseINDIVIOR UK LTD·Filed 2025·Application pending·0 cites
- 4057US2025255861A1Methods for administering buprenorphineINDIVIOR UK LTD·Filed 2024·Application pending·0 cites
- 4152US2018243292A1Sustained-release buprenorphine formulationsINDIVIOR UK LTD·Filed 2017·Application pending·0 cites
- 4251US10584135B2Substituted 3,6-diazabicyclo[3.2.0]heptanesINDIVIOR UK LTD·Filed 2019·Granted Mar 10, 2020·0 cites·19 claims
- 4346US2021386745A1Methods for treating schizophreniaINDIVIOR UK LTD·Filed 2020·Application pending·0 cites
- 4443US2019015415A1Methods for treating schizophreniaINDIVIOR UK LTD·Filed 2018·Application pending·0 cites
- 4541US2018313858A1Quantification of drugs in biological samplesINDIVIOR UK LTD·Filed 2016·Application pending·0 cites
- 4639US2021393618A1Buprenorphine to treat respiratory depressionINDIVIOR UK LTD·Filed 2019·Application pending·0 cites
- 4735US2019046532A1Psychiatric treatment for patients with gene polymorphismsINDIVIOR UK LTD·Filed 2016·Application pending·0 cites
- 4833US10577361B2Dopamine D3 receptor antagonists having a morpholine moietyINDIVIOR UK LTD·Filed 2016·Granted Mar 3, 2020·0 cites·18 claims
- 4931US2019029966A1Abuse-resistant pharmaceutical formulationsINDIVIOR UK LTD·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when INDIVIOR UK LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →